FDA-approved generic pergolide reaches horses with PPID

CURRENT BRIEF VERSION: Zygolide, the first FDA-approved generic pergolide tablet for horses with pituitary pars intermedia dysfunction, or PPID, entered the U.S. market in January 2026, giving equine veterinarians a new prescription option alongside brand-name Prascend. FDA said Zygolide is bioequivalent to Prascend, which was first approved in 2011, and approved the product on December 19, 2025, with a public announcement on January 9, 2026. Dechra is positioning the product around easier daily administration and quality-of-life messaging, highlighting its peppermint flavor, 360-degree scoring for tablet splitting, lower-cost generic status, and consumer-facing campaign language such as “Rediscover the partnership with Zygolide” and “Help your horse feel their best so you can enjoy more happy moments together.” (fda.gov; thehorse.com)

Why it matters: PPID is a chronic condition that often requires lifelong treatment, so a generic pergolide option could improve adherence for some pet parents by lowering cost and offering more flexible dosing. For veterinary professionals, the launch may create more room for individualized conversations about dosing, tablet handling, monitoring, and owner expectations, especially as Dechra’s marketing leans into preserving the horse-owner partnership and day-to-day well-being rather than simply matching the brand reference product. Clinicians still need to reinforce that tablets should not be crushed because of human exposure risks and that appetite loss, weight loss, lethargy, or behavioral changes can emerge early in treatment. (fda.gov)

What to watch: Watch for how quickly equine practices and pharmacies adopt Zygolide, whether Dechra’s owner-focused messaging helps uptake, and whether the new generic meaningfully changes long-term treatment adherence and affordability for horses with PPID. (thehorse.com)